主页 > 医学文档 >
【drug-news】利用细菌来合成具有复杂结构的抗肿
Source: University of Warwick
Date: November 1, 2006
Bacteria Could Make New Library Of Cancer Drugs That Are Too Complex To Create Artificially
Researchers at the University of Warwick are examining a way of using bacteria to manufacture a new suite of potential anti-cancer drugs that are difficult to create synthetically on a lab bench.
The bacterium Streptomyces coelicolor naturally produce antibiotics called prodiginines.
This group of antibiotics has stimulated much recent interest as they can be used to target and kill cancer cells. A synthetic prodiginine analogue called GX15-070 is currently in phase 1 and 2 cancer treatment trials. However, analogues of other prodiginines, such as streptorubin B, could be even more powerful anti cancer tools, but they cannot currently be easily synthetically produced on a lab bench.
Professor Greg Challis and colleagues in the Chemistry Department of the University of Warwick have looked at the enzymes controlling the process that allows the bacterium Streptomyces coelicolor to create streptorubin B and have gained a clear understanding of which are the key enzymes that act at particular steps of that process. By manipulation of the enzyme content of the bacteria, they aim to produce a range of different compounds based closely on the form of streptorubin B normally formed by the bacteria. Some of these analogues of streptorubin B could provide the basis for developing useful new anti cancer drugs.
Professor Challis said: "This approach combines the strengths of conventional organic synthesis, with the synthetic power of biology, to assemble complex and synthetically difficult structures. It could be particularly valuable for generating analogues of streptorubin B with all the promise that holds for the development of new anti cancer drugs" 本人已认领该文编译，48小时后若未提交译文，请其他战友自由认领 微生物——抗肿瘤药物的加工厂
Bacteria Could Make New Library Of Cancer Drugs That Are Too Complex To Create Artificially
一些抗肿瘤药物由于结构过于复杂使得人工合成难以进行。科学家可以利用微生物来合成这类新的药物。
Researchers at the University of Warwick are examining a way of using bacteria to manufacture a new suite of potential anti-cancer drugs that are difficult to create synthetically on a lab bench.
Warwick大学的研究者探讨了利用微生物来制造人工难以合成的潜在抗肿瘤药物的方法。
The bacterium Streptomyces coelicolor naturally produce antibiotics called prodiginines.
天蓝色链霉菌可产生名为灵杆菌素的抗生素。
This group of antibiotics has stimulated much recent interest as they can be used to target and kill cancer cells. A synthetic prodiginine analogue called GX15-070 is currently in phase 1 and 2 cancer treatment trials. However, analogues of other prodiginines, such as streptorubin B, could be even more powerful anti cancer tools, but they cannot currently be easily synthetically produced on a lab bench.
这一类抗生素最近激发了研究者们的兴趣，因为它们可用于靶向杀灭肿瘤细胞。人工合成的灵杆菌素类似物（名为GX15-070）目前正处于一期和二期癌症治疗的临床试验研究中，研究还发现该种抗生素的其它类似物如链玉红菌素B，其抗肿瘤活性更为强大，但目前这些药物在实验室环境下难于合成。
Professor Greg Challis and colleagues in the Chemistry Department of the University of Warwick have looked at the enzymes controlling the process that allows the bacterium Streptomyces coelicolor to create streptorubin B and have gained a clear understanding of which are the key enzymes that act at particular steps of that process. By manipulation of the enzyme content of the bacteria, they aim to produce a range of different compounds based closely on the form of streptorubin B normally formed by the bacteria. Some of these analogues of streptorubin B could provide the basis for developing useful new anti cancer drugs.
Warwick大学化学系的Greg Challis教授和他的同事研究了天蓝色链霉菌合成链玉红菌素B控制过程中发挥作用的酶，透彻地理解了其中特定步骤中的关键酶。通过控制微生物的酶，他们的目标是合成大量不同的，结构均基于链玉红菌素B的化合物。其中一些类似物或许能成为研发新抗肿瘤药物的基础。
Professor Challis said: "This approach combines the strengths of conventional organic synthesis, with the synthetic power of biology, to assemble complex and synthetically difficult structures. It could be particularly valuable for generating analogues of streptorubin B with all the promise that holds for the development of new anti cancer drugs"
Challis教授说：“这种方法集常规有机合成与生物合成的优势于一体，用于合成那些结构复杂，难于人工合成的化合物。这种方法对于合成链玉红菌素B的类似物尤其具有价值，它们是一类充满希望的新型抗肿瘤药物。” Sina编译
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-06-15 05:11
医学,生命科学网